Akeso Biopharma’s Ebdarokimab (AK101) NDA Accepted for Review by China’s CDE
China-based Akeso Biopharma (HKG: 9926) has announced that the New Drug Application (NDA) for its...
HKG: 9926
Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results
Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023,...
Akeso Biopharma’s Ebronucimab NDA Accepted for Review by China’s NMPA
China-based Akeso Biopharma (HKG: 9926) has announced that the National Medical Products Administration (NMPA) has...
Akeso Biopharma Initiates Phase III Study for Ivonescimab in Non-Small Cell Lung Cancer
China-based Akeso Biopharma (HKG: 9926) has announced the initiation of a Phase III clinical study...
Specialised Therapeutics to Commercialize Akeso’s PD-1 Inhibitor Penpulimab in APAC
Singapore-based Specialised Therapeutics Asia Pte Ltd (ST) has been appointed to handle the commercialization of...
Akeso Biopharma and LaNova Medicines Collaborate on Clinical Studies for Cancer Therapies
China-based Akeso Biopharma (HKG: 9926) has announced a strategic partnership with fellow Chinese firm LaNova...
Akeso Biopharma Reports 422% Increase in Product Sales, Boosted by Cadonilimab and Penpulimab
China-based Akeso Biopharma (HKG: 9926) released its 2022 financial report, highlighting significant growth in product...
Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer
China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...
Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment
China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai...
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...
Akeso Receives First $300M Installment from Summit for Bispecific Antibody Ivonescimab
Akeso Inc. (HKG: 9926) has announced receiving the first installment of USD 300 million as...
Akeso’s Penpulimab Secures New Approval for Lung Cancer Indication
China-based Akeso Biopharma (HKG: 9926) has announced receiving another indication approval from the National Medical...
Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics
A new bar was set for the most valuable out-license deal struck by a China-based...
Akeso Biopharma Plans IPO on Shanghai’s STAR Market
China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...
Akeso Biopharma’s AK112 Receives Two New Breakthrough Therapy Designations
The Center for Drug Evaluation (CDE) website indicates that China-based Akeso Biopharma (HKG: 9926) has...
Akeso Biopharma Completes Enrollment for AK112 Phase III Study
China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...
Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer
China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included...
Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study
China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration...
Akeso Biopharma’s H1 2022 Revenue Rises 26.8% on Penpulimab Sales
China-based Akeso Biopharma (HKG: 9926) reported RMB 163 million (USD 23.8 million) in revenue for...
Akeso Biopharma’s Cadonilimab Achieves National Delivery in China
China-based biotech Akeso Biopharma (HKG: 9926) announced the national delivery of its cadonilimab (AK104), marking...